# A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

> **NCT05738486** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1175 (actual)

## Conditions studied

- Alzheimer's Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Placebo
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05738486
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-28
- **Primary completion:** 2024-05-16
- **Final completion:** 2027-05
- **Target enrollment:** 1175 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738486, "A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05738486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*